EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 22 / No 4 (Avril 2006) Med Sci (Paris), 22 4 (2006) 437-443 References
Free Access
Issue
Med Sci (Paris)
Volume 22, Number 4, Avril 2006
Page(s) 437 - 443
Section Recherche et partenariat
DOI https://doi.org/10.1051/medsci/2006224437
Published online 15 April 2006
  1. Hamberg M, Svennsson J, Samuelson B. Thromboxanes : a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72 : 2994–8. [Google Scholar]
  2. Vane JR, Flower R, Botting RM. The mechanism of action of aspirin. In : Vane JR, Botting RM, eds. Aspirin and other salicylates. London : Chapman and Hall Medical, 1992 : 35–59. [Google Scholar]
  3. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101 : 1206–18. [Google Scholar]
  4. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors : structures, properties, and functions. Physiol Rev 1999; 79 : 1193–226. [Google Scholar]
  5. Halushka PV. Thromboxane A2 receptors : where have you gone ? Prostagl Lipid Med 2000; 60 : 175–89. [Google Scholar]
  6. Hirata M, Ushikubi F, Kakizuka A, et al. Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivities to Arg60 to Leu mutation. J Clin Invest 1996; 97 : 949–56. [Google Scholar]
  7. Kinsella BT. Thromboxane A2 signalling in humans : a "tail" of two receptors. Biochem Soc Trans 2001 : 29 : 641–54. [Google Scholar]
  8. Hall SE. Thromboxane A2 receptor antagonists. Med Res Rev 1991; 11 : 503–79. [Google Scholar]
  9. Dogné JM, Hanson J, de Leval X, et al. New developments on thromboxane modulators. Mini Rev Med Chem 2004; 4 : 649–57. [Google Scholar]
  10. Verbeuren TJ, Simonet S, Descombes JJ, et al. S 18204 : a new powerful TXA2-receptor antagonist with a long duration of action. Thromb Haemost 1995; 73 : 1324. [Google Scholar]
  11. Cimetière B, Dubuffet T, Muller O, et al. Synthesis and biological evaluation of new tetrahydronaphthalene derivatives as thromboxane receptor antagonists. Bioorg Med Chem Lett 1998; 8 : 1375–80. [Google Scholar]
  12. Verbeuren TJ, Vallez MO, Petit C, et al. Amelioration of albuminuria in the diabetic rat by S 18204, an anti-thromboxane receptor antagonist. Circulation 1995; 92 : 222. [Google Scholar]
  13. Simonet S, Descombes JJ, Vallez MO, et al. S 18886, a new thromboxane (TP)-receptor antagonist is the active isomer of S 18204 in all species, except in the guinea-pig. In : Sinzinger H et al., eds. Recent advances in prostaglandin, thromboxane and leukotriene research. New York : Plenum Press, 1998 : 173–6. [Google Scholar]
  14. Vallez MO, Rupin A, De Nanteuil G, Verbeuren T. Synergistic antithrombotic effects of the TP-receptor antagonist S 18886 and the direct thrombin inhibitor S 31307 in a thrombosis model of the rat abdominal aorta. Thromb Haemost 2001; P1625. [Google Scholar]
  15. Verbeuren T, Descombes JJ, Simonet S, et al. The TP-receptor antagonist S 18886 unmasks vascular relaxation and potentiates the anti-platelet action of PGD2. Thromb Haemost 1997; 693. [Google Scholar]
  16. Descombes JJ, Menant Y, Lavielle G, Verbeuren TJ. Binding properties of a potent, long acting new thromboxane receptor antagonist, [3H] S 18886, on human, rat and dog platelet membranes. Br J Pharmacol 1997; 122 : 381P. [Google Scholar]
  17. Gaussem P, Rény JL, Thalamas C, et al. The specific thromboxane receptor antagonist S 18886 : pharmacokinetic and pharmacodynamic studies. J Thromb Haemost 2005; 3 : 1437–45. [Google Scholar]
  18. Belhassen L, Pelle G, Dubois-Rande JL, Adnot S. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003; 41 : 1198–204. [Google Scholar]
  19. Taddei S, Virdis A, Ghiadoni L, et al. Endothelial dysfunction in hypertension. J Cardiovasc Pharmacol 2001; 38 : S11–4. [Google Scholar]
  20. Yang D, Félétou M, Levens N, et al. A diffusible substance(s) mediates endothelium-dependent contractions in the aorta of SHR. Hypertension 2003; 41 : 143–8. [Google Scholar]
  21. Maalej N, Osman HE, Shanmuganayagam D, et al. Antithrombotic properties of the thromboxane A2/prostaglandin H2 receptor antagonist S18886 on prevention of platelet-dependent cyclic flow reductions in dogs. J Cardiovasc Pharmacol 2005; 45 : 389–95. [Google Scholar]
  22. Osende JI, Shimbo D, Fuster V, et al. Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist. J Thromb Haemost 2004; 2 : 492–8. [Google Scholar]
  23. Verbeuren TJ, Jordaens FH, Zonnekeyn LL, et al. Effect of hypercholesterolemia on vascular reactivity in the rabbit. I. Endothelium-dependent and endothelium-independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits. Circ Res 1986; 58 : 552–64. [Google Scholar]
  24. Verbeuren TJ. Endothelium and coronary atherosclerosis, an update. Coronary Artery Disease 1993; numéro spécial : 72–87. [Google Scholar]
  25. Cayatte AJ, Du Y, Oliver-Krasinski J, et al. The thromboxane-receptor antagonist, S 18886 but not aspirin inhibits atherogenesis in apolipoprotein E deficient mice : evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20 : 1724–8. [Google Scholar]
  26. Osborne JA, Lefer AM. Cardioprotective actions of thromboxane receptor antagonism in ischemic atherosclerotic rabbits. Am J Physiol 1988; 255 : H318–24. [Google Scholar]
  27. Van Diest M, Herman AG, Verbeuren TJ. Influence of hypercholesterolemia on the reactivity of isolated rabbit arteries to 15-lipoxygenase metabolites of arachidonic acid : comparison with platelet-derived agents and vasodilators. Prostaglandins Leukot Essent Fatty Acids 1996; 54 : 135–45. [Google Scholar]
  28. Montuschi P, Barnes PJ, Roberts LJII. Isoprostanes : markers and mediators of oxidative stress. FASEB J 2004; 18 : 1791–800. [Google Scholar]
  29. Ishizuka T, Suzuki K, Kawakami M, et al. Thromboxane A2 receptor blockade suppresses intercellular adhesion molecule-1 expression by stimulated vascular endothelial cells. Eur J Pharmacol 1996; 312 : 367–77. [Google Scholar]
  30. Kobayashi T, Tahara Y, Matsumoto M, et al. Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004; 114 : 784–94. [Google Scholar]
  31. Zuccollo A, Shi C, Mastroani R, et al. The thromboxane A2 receptor antagonist, S 18886, prevents enhanced atherogenesis caused by diabetes mellitus. Circulation 2005; 112 : 3001–8. [Google Scholar]
  32. Ishizuka T, Matsui T, Kurita A. Ramatroban, a TP receptor antagonist, improves vascular responses to acetylcholine in hypercholesterolemic rabbits in vivo. Eur J Pharmacol 2003; 468 : 27–35. [Google Scholar]
  33. Egan KM, Wang M, Lucitt MB, et al. Cyclooxygenases, thromboxane, and atherosclerosis : plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005; 111 : 334–42. [Google Scholar]
  34. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296 : 539–41. [Google Scholar]
  35. Worth NF, Berry CL, Thomas AC, Campbell JH. S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis 2005; 183 : 65–73. [Google Scholar]
  36. Viles-Gonzalez JF, Fuster V, Corti R, et al. Atherosclerosis regression and TP receptor inhibition : effect of S 18886 on plaque size and composition. A magnetic resonance imaging study. Eur Heart J 2005; 26 : 1557–61. [Google Scholar]
  37. Xu S, Maitland KA, Jiang B, et al. The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic Apo E-deficient mice. Diabetes 2006; 55 : 110–9. [Google Scholar]
  38. Simmons TR, Cook JA, Moore JN, Halushka PV. Thromboxane A2 receptors in equine monocytes : identification of a new subclass of TXA2 receptors. J Leukoc Biol 1993; 53 : 173–8. [Google Scholar]
  39. Nagata T, Uehara Y, Numabe A, et al. Regulatory effect of thromboxane A2 on proliferation of vascular smooth muscle cells from rats. Am J Physiol 1992; 263 : H1331–8. [Google Scholar]
  40. Gao Y, Yokota R, Tang S, et al. Reversal of angiogenesis in vitro, induction of apoptosis, and inhibition of Akt phosphorylation in endothelial cells by thromboxane A2. Circ Res 2000; 87 : 739–45. [Google Scholar]
  41. Verbeuren TJ, Cohen RA. Role of TP-receptors in atherosclerosis and vascular endothelial dysfunction. In : Abstracts of the Symposium on endothelial factors and coronary disease. Hong Kong, China, 2004 : 22 (abstract). [Google Scholar]
  42. Tang M, Cyrus T, Yao Y, et al. Involvement of thromboxane receptor in the proatherogenic effect of isoprostane F2a-III. Evidence from apolipoprotein E- and LDL receptor-deficient mice. Circulation 2005; 112 : 2867–74. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.